Upstate Active Clinical Trials

Study Title:

Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

What is the purpose of the study?

Randomized treatment study to look at the effect of temozolomide & irinotecan hydrochloride together with or without bevacizumab in treating young patients with recurrent or refractory medulloblastoma or CNS primitive neuroectodermal tumors.

Upstate Institutional Review Board (IRB) Number:

263526

Study/Protocol ID:

ACNS0821

Study Phase:

II

Patient Age Group:

Children

Principal Investigator:

Karol H Kerr, MD

ClinicalTrials.Gov ID:

NCT01217437

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Beatriz Kovar
Phone: 315-464-7232
Email: kovarb@upstate.edu

Return to Previous Page || Search Again